SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-077410
Filing Date
2023-07-03
Accepted
2023-07-03 08:00:25
Documents
12
Period of Report
2023-06-30
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2320415d1_8k.htm   iXBRL 8-K 23018
  Complete submission text file 0001104659-23-077410.txt   195429

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nvct-20230630.xsd EX-101.SCH 2959
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvct-20230630_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvct-20230630_pre.xml EX-101.PRE 22359
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2320415d1_8k_htm.xml XML 3572
Mailing Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024
Business Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024 360-837-7232
Nuvectis Pharma, Inc. (Filer) CIK: 0001875558 (see all company filings)

IRS No.: 862405608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41264 | Film No.: 231063626
SIC: 2834 Pharmaceutical Preparations